In vitro susceptibilities of Bartonella and Rickettsia spp. to fluoroquinolone antibiotics as determined by immunofluorescent antibody analysis of infected Vero cell monolayers

International Journal of Antimicrobial Agents

Volumn 18, Issue 3, 2001, Pages 217-222

  Ives, Timothy J ^a   Marston, Eric L ^b   Regnery, Russell L ^b   Butts, John D ^c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c University of Kentucky   (United States)

Author keywords

Bartonella; Fluoroquinolones; In vitro; Rickettsia

Indexed keywords

CIPROFLOXACIN; LEVOFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN;

ANIMAL CELL; ANTIBIOTIC SENSITIVITY; ARTICLE; BARTONELLA; BARTONELLA HENSELAE; BARTONELLA QUINTANA; CONTROLLED STUDY; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RICKETTSIA; RICKETTSIA CONORII; RICKETTSIA PROWAZEKII; RICKETTSIA RICKETTSII; VERO CELL;

ANIMALS; ANTI-INFECTIVE AGENTS; BARTONELLA; CERCOPITHECUS AETHIOPS; COLONY COUNT, MICROBIAL; FLUORESCENT ANTIBODY TECHNIQUE; FLUOROQUINOLONES; MICROBIAL SENSITIVITY TESTS; RICKETTSIA; VERO CELLS;

EID: 0034776040     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(01)00388-0     Document Type: Article

References (47)

1. Chronic Bartonella quintana bacteremia in homeless patients
2. Bartonella henselae prevalence in domestic cats in California: risk factors and association between bacteremia and antibody titers
3. Syndrome of Rochalimaea henselae adenitis suggesting cat scratch disease
4. Prevalence of Bartonella henselae and Bartonella clarridgeiae in an urban Indonesian cat population
5. Characterization of a novel Rochalimaea species, R. henselae sp. nov., isolated from blood of a febrile, human immunodeficiency virus-positive
6. Rochalimaea henselae sp. nov., a cause of septicaemia, bacillary angiomatosis, and parenchymal bacillary peliosis
7. Rochalimaea elizabethae sp. nov. isolated from a patient with endocarditis
8. Rats of the genus Rattus are reservoir hosts for pathogenic Bartonella species: an Old World origin for a New World disease?
9. Susceptibility of Rickettsia conorii, R. rickettsii and Coxiella burnetti to PD 127,391, PD 131,628, pefloxacin, ofloxacin, and ciprofloxacin
10. Evaluation of the anti-Rickettsial activity of fluoroquinolones
11. Bacteriostatic and bacteriocidal activity of levofloxacin against Rickettsia rickettsii, Rickettsia conorii, 'Israel spotted fever group rickettsia' and Coxiella burnetti
12. In vitro antibiotic susceptibility of Rickettsia conorii to ciprofloxacin as determined by suppressing lethality in chicken embryos and by plaque assay
13. In vitro susceptibilities of Coxiella burnetti, Rickettsia rickettsii and Rickettsia conorii to the fluoroquinolone sparfloxacin
14. Multiple-dose pharmacokinetics of sparfloxacin and its influence on fecal flora
15. In vitro susceptibilities of 27 Rickettsiae to 13 antimicrobials
16. Efficacy of enrofloxacin or doxycycline for treatment of Bartonella henselae or Bartonella clarridgeiae infection in cats
17. Antimicrobial susceptibilities of Rochalimaea quintana, Rochalimaea vinsonii, and the newly recognized Rochalimaea henselae
18. MICs of 28 antibiotic compounds for 14 Bartonella (formerly Rochalimaea) isolates
19. Lack of bactericidal effect of antibiotics except aminoglycosides on Bartonella (Rochalimaea) henselae
20. Antibiotic susceptibility patterns in Rochalimaea quintana, the agent of trench fever
21. The Etest for antimicrobial susceptibility testing of Bartonella henselae
22. In vitro susceptibilities of four Bartonella bacilliformis strains to 30 antibiotic compounds
23. In vitro susceptibilities of Bartonella henselae, B. quintana, B. elizabethe, Rickettsia rickettsii, R. conorii, R. akari, and R. prowazekii to macrolide antibiotics as determined by immunofluorescent-antibody analysis of infected Vero cell monolayers
24. In vitro susceptibilities of Rickettsia and Bartonella spp. to 14-hydroxy-clarithromycin as determined by immunofluorescent antibody analysis of infected Vero cell monolayers
25. Bartonella henselae and Bartonella quintana adherence to and entry into cultured human epithelial cells
26. Serological response to 'Rochalimaea henselae' antigen in suspected cat-scratch disease
27. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men
28. Pharmacodynamics of levofloxacin. A new paradigm for early clinical trials
29. Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers
30. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses
31. Pharmacokinetics of ofloxacin and the effect on faecal flora of healthy volunteers
32. Pharmacokinetics of sparfloxacin in healthy volunteers and patients: a review
33. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis
34. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
35. Intracellular distribution and activity of antibiotics
36. Entry of lomefloxacin and temafloxacin into human neutrophils, peritoneal macrophages, and tissue culture cells
37. Uptake and intracellular activity of sparfloxacin in human polymorphonuclear leukocytes and tissue culture cells
38. Influence of bactericidal-antibiotic interactions on subsequent antimicrobial activity of alveolar macrophages
39. Uptake of antibiotics by human polymorphonuclear leukocyte cytoplasts
40. Antibiotic uptake by alveolar macrophages
41. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome: focus on antibacterial agents
42. Comparison of E-test to broth microdilution method for testing Streptococcus pneumoniae susceptibility to levofloxacin and three macrolides
43. Synthesis and antibacterial activities of optically active ofloxacin
44. Mechanism underlying levofloxacin uptake by human polymorphonuclear neutrophils
45. Uptake and intracellular activity of ofloxacin isomers in human phagocytic and non-phagocytic cells
46. Uptake and intracellular activity of an optically active ofloxacin isomer in human neutrophils and tissue culture cells
47. Uptake, accumulation and egress of erythromycin by tissue culture cells of human origin